Pathios Therapeutics Welcomes Dr. Sumeet Ambarkhane as New Chief Medical Officer
Pathios Therapeutics Limited, a forward-thinking biotech firm dedicated to developing innovative cancer therapies, is excited to announce the appointment of Dr. Sumeet Ambarkhane, M.D., as its new Chief Medical Officer (CMO). This strategic hire comes as Pathios embarks on a crucial phase of clinical development for its promising oncology programs, particularly its lead investigational drug PTT-4256.
Dr. Ambarkhane is a seasoned medical professional with over 20 years of extensive experience in clinical care and biopharmaceutical development. His previous role as CMO at Alligator Bioscience allowed him to steer the company’s preclinical and clinical strategies focusing on tumor-targeted immunotherapies. Under his guidance, Alligator successfully advanced mitazalimab towards Phase 3 clinical trials in pancreatic cancer, showcasing Dr. Ambarkhane's capability to guide drug development from conception through regulatory approval.
Prior to his tenure at Alligator, Dr. Ambarkhane served as Senior Global Program Medical Director at MorphoSys AG. His leadership was instrumental in the development of tafasitamab (Monjuvi®/Minjuvi®), a drug that received both breakthrough therapy designation and accelerated approval from the FDA. His diverse background also includes significant roles at UCB Pharmaceuticals, where he contributed to the advancement of treatments in immunology and neurology.
Holding degrees in medicine and clinical pharmacology from Seth G.S. Medical College and the University of Mumbai, Dr. Ambarkhane blends academic rigor with real-world clinical insights. His rich experience in drug development is expected to greatly benefit Pathios as it pushes the boundaries in the oncology field.
Pathios is particularly known for its first-in-class approach to targeting GPR65, a G protein-coupled receptor that plays a key role in the immune system's response to tumors. The company’s lead compound, PTT-4256, is formulated to inhibit GPR65, thereby enhancing the immune system's ability to attack solid tumors. This innovative approach is supported by compelling preclinical data that suggest GPR65 inhibition significantly improves survival rates across various cancer types.
As Dr. Ambarkhane joins Pathios, the company is keen to leverage his expertise to enhance the clinical trial momentum for its ongoing projects, especially the PTT-4256, currently under evaluation in the RAISIC-1 trial. This Phase 1/2 clinical study aims to assess the drug's efficacy in patients with advanced solid tumors and stands as a testament to Pathios’ commitment to pioneering cancer treatment.
In addition to oncology, Pathios is exploring GPR65’s potential in treating other immunologically-related conditions, such as neuroinflammatory diseases, based on genetic evidence linking GPR65 to disorders like Alzheimer's disease and Parkinson's disease.
"Bringing in such a highly skilled CMO at this pivotal moment positions us strongly for 2025 and beyond," remarked Paul Higham, CEO of Pathios. "With Dr. Ambarkhane’s wealth of experience, we are more equipped than ever to innovate and deliver meaningful therapies to patients in need." Dr. Ambarkhane expressed enthusiasm about joining Pathios, emphasizing the unique opportunity to work with a team dedicated to making significant strides in cancer therapeutics.
This appointment marks a significant milestone for Pathios Therapeutics, reflecting its dedication to advancing innovative science into effective therapies. With the industry rapidly evolving and the need for novel cancer treatments pressing, Dr. Ambarkhane's leadership is set to propel Pathios into its next chapter of groundbreaking research and clinical success.
Dr. Ambarkhane is a seasoned medical professional with over 20 years of extensive experience in clinical care and biopharmaceutical development. His previous role as CMO at Alligator Bioscience allowed him to steer the company’s preclinical and clinical strategies focusing on tumor-targeted immunotherapies. Under his guidance, Alligator successfully advanced mitazalimab towards Phase 3 clinical trials in pancreatic cancer, showcasing Dr. Ambarkhane's capability to guide drug development from conception through regulatory approval.
Prior to his tenure at Alligator, Dr. Ambarkhane served as Senior Global Program Medical Director at MorphoSys AG. His leadership was instrumental in the development of tafasitamab (Monjuvi®/Minjuvi®), a drug that received both breakthrough therapy designation and accelerated approval from the FDA. His diverse background also includes significant roles at UCB Pharmaceuticals, where he contributed to the advancement of treatments in immunology and neurology.
Holding degrees in medicine and clinical pharmacology from Seth G.S. Medical College and the University of Mumbai, Dr. Ambarkhane blends academic rigor with real-world clinical insights. His rich experience in drug development is expected to greatly benefit Pathios as it pushes the boundaries in the oncology field.
Pathios is particularly known for its first-in-class approach to targeting GPR65, a G protein-coupled receptor that plays a key role in the immune system's response to tumors. The company’s lead compound, PTT-4256, is formulated to inhibit GPR65, thereby enhancing the immune system's ability to attack solid tumors. This innovative approach is supported by compelling preclinical data that suggest GPR65 inhibition significantly improves survival rates across various cancer types.
As Dr. Ambarkhane joins Pathios, the company is keen to leverage his expertise to enhance the clinical trial momentum for its ongoing projects, especially the PTT-4256, currently under evaluation in the RAISIC-1 trial. This Phase 1/2 clinical study aims to assess the drug's efficacy in patients with advanced solid tumors and stands as a testament to Pathios’ commitment to pioneering cancer treatment.
In addition to oncology, Pathios is exploring GPR65’s potential in treating other immunologically-related conditions, such as neuroinflammatory diseases, based on genetic evidence linking GPR65 to disorders like Alzheimer's disease and Parkinson's disease.
"Bringing in such a highly skilled CMO at this pivotal moment positions us strongly for 2025 and beyond," remarked Paul Higham, CEO of Pathios. "With Dr. Ambarkhane’s wealth of experience, we are more equipped than ever to innovate and deliver meaningful therapies to patients in need." Dr. Ambarkhane expressed enthusiasm about joining Pathios, emphasizing the unique opportunity to work with a team dedicated to making significant strides in cancer therapeutics.
This appointment marks a significant milestone for Pathios Therapeutics, reflecting its dedication to advancing innovative science into effective therapies. With the industry rapidly evolving and the need for novel cancer treatments pressing, Dr. Ambarkhane's leadership is set to propel Pathios into its next chapter of groundbreaking research and clinical success.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.